Navigation Links
Micromet Announces Changes in Management Team
Date:12/14/2007

BETHESDA, Md., Dec. 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) ("Micromet" or the "Company"), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the resignation of Christopher Schnittker as Senior Vice President and Chief Financial Officer. Donald A. Zelm, Executive Director Finance, will assume the responsibilities as principal financial officer of the Company and as its interim chief financial officer. He will oversee the Company's financial operations until a new chief financial officer is hired. The Company has initiated a search for a new CFO.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the first antibody in Micromet's product pipeline developed utilizing the BiTE(R) antibody technology platform, is being evaluated in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia, and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, a subsidiary of Astra Zeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumab is being developed by Micromet in collaboration with Merck Serono in a phase
'/>"/>

SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Stryker brand ambassadors ... week at the 3M Championship Champions Tour event near ... in Blaine . Stryker is the official joint ... Starting Friday, August 1 st through Sunday, August ... Mobility Zone; an on-site joint health destination located in the Pioneer ...
(Date:7/30/2014)... , July 30, 2014 Silicon Valley Bank, ... a study today that examines the merger, acquisition ... device companies.  According to the annual report based on ... potential returns since SVB started tracking the data in ... IPO.  Built on solid healthcare M&A activity over the ...
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... the global leader in technology support and BPO services ... today the opening of its new Global Operations Center ... city of Dalian, will specialize in providing services in ... sponsors and clinical research organizations. With dramatic ...
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
Cached Medicine Technology:C3i Opens Asia Language Center in Dalian, China 2Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3
(Date:7/30/2014)... 30, 2014 Decene is an ... chain of ten carbon atoms with one double ... of 1-decenes. It can be used as a ... to produce epoxides, amines, oxo alcohols, synthetic lubricants, ... Early buyers will receive 10% customization on this ...
(Date:7/30/2014)... Washington, D.C. (PRWEB) July 30, 2014 ... Community Anti-Drug Coalitions of America (CADCA) , the ... statement in response to the New York Times ... published on Sunday, July 27th. , “CADCA is ... their very public call for national marijuana legalization. The ...
(Date:7/30/2014)... Washington, DC (PRWEB) July 30, 2014 ... have recently joined the Board of Directors of ... provides guidance for the Association, which has a ... in healthcare delivery through telecommunications and information technology. ... members of the Association, possess extraordinary expertise and ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- Medical costs ... States are more than $32 billion each year, according ... Control and Prevention. The yearly financial toll of ... to reach an estimated $49 billion by 2020. ... for COPD, which provide state public health practitioners with ...
(Date:7/30/2014)... whether a person is at risk for suicide could lie ... Chemical changes to a gene involved in the brain,s response ... the study,s authors explained. Spotting those changes in a blood ... suicide, they said. "Suicide is a major preventable public ... efforts because we have no consistent way to predict those ...
Breaking Medicine News(10 mins):Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:CADCA Responds to New York Times Editorial Board's Call for Marijuana Legalization 2Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3
... danger, study warns , MONDAY, June 1 (HealthDay News) ... eat enough to cover their energy output face the ... female athletes in the same circumstances, new research suggests. ... place dancers at higher risk for the "cardiovascular ...
... OTTAWA, June 1 /PRNewswire-FirstCall/ - MDS Nordion, a leading ... of,Canada and Atomic Energy of Canada Limited (AECL) to ... the MAPLE,project to address the current shortage of medical ... (NRU) reactor at Chalk River,Ontario - and to avoid ...
... EMERYVILLE, Calif., June 1 Bayer HealthCare Pharmaceuticals, Inc. ... today announced that the companies have begun enrolling patients ... (sorafenib) tablets in patients with non-squamous non-small cell lung ... treatments. , , "Nexavar has proven efficacy in ...
... Expands Veran,s electromagnetic (EM) navigation for oncology procedures. ... Veran Medical Technologies announced today that it has ... property. Veran secured a worldwide license to ... The Navigation division of Medtronic has developed ...
... twenty-somethings who attend or have graduated from private religious ... peers from public schools, according to sociological research published ... Health and Social Behavior . "This research suggests ... of social, financial and health-related factors that can make ...
... International (NYSE: VRX ) announced today that it ... SGP ) for taribavirin in Japan. In ... and release its last right of refusal on taribavirin under ... pursue partnering arrangements for the rest of the world. ...
Cached Medicine News:Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 2Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 3Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 4Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 5Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 2Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 3Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 4Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 5Health News:Veran Medical Technologies Announces Intellectual Property Agreement With Medtronic 2Health News:Religious devotion does not impact abortion decisions of young unwed women 2Health News:Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 2Health News:Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 3
... COMBO 2 Assay is a second generation ... capture for in vitro qualitative detection and ... The assay uses a family of Gen-Probe's ... Amplification (TMA) and Dual Kinetic Assay (DKA). ...
... is a novel device for the ... gonorrhoeae and Neisseria meningitidis. This ... and is easily transportable as a ... incubate and examine the growth of ...
... NearVision™ CK is the only procedure designed for ... and +3.00 D or presbyopic patients who would ... D and 2.25 D to achieve a myopic ... in their non-dominant eye to temporarily improve near ...
... The CC-7000 is a mid range space ... take a non-contact picture of the corneal endothelium ... the corneal thickness in the central area. The ... 9" monitor, which is supplied with the system., ...
Medicine Products: